Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Nancy L. Bartlett, Brian A. Costello, Betsy R. LaPlant, Stephen M. Ansell, John G. Kuruvilla, Craig B. Reeder, Lim S. Thye, Daniel M. Anderson, Kilannin Krysiak, Cody Ramirez, Jing Qi, Barry A. Siegel, Malachi Griffith, Obi L. Griffith, Felicia Gomez, Todd A. Fehniger

Blood (2018) 131 (2): 182–190.

https://doi.org/10.1182/blood-2017-09-804641

Published: 2018

Includes: Supplemental data

Journal Articles

Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience

Umberto Falcone, MD PhD, Melania Pintilie, MSc, Ri Wang, Vishal Kukreti, MD, John G. Kuruvilla, MD, Jan M.A. Delabie, MD PhD, Richard Tsang, MD, Michael Crump, MD

Blood (2016) 128 (22): 3005.

https://doi.org/10.1182/blood.V128.22.3005.3005

Published: 2016

Journal Articles

Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma

Matthew D. Cooper, Umberto Falcone, MD PhD, Naom Tau, MD, Eshetu G Atenafu, M.Sc., P.Stat., Richard Tsang, MD, David C. Hodgson, MD, Armand Keating, MD, Ur Metser, MD, Michael Crump, MD, John G. Kuruvilla, MD

Blood (2016) 128 (22): 4645.

https://doi.org/10.1182/blood.V128.22.4645.4645

Published: 2016

Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 586.

https://doi.org/10.1182/blood.V126.23.586.586

Published: 2015

Journal Articles

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth A Christian, MD, John G. Kuruvilla, MD, Sonali M. Smith, MD, Pierluigi Porcu, MD, Kami J. Maddocks, MD, Amy S. Ruppert, MAS, John C Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2015) 126 (23): 3983.

https://doi.org/10.1182/blood.V126.23.3983.3983

Published: 2015

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre

Jeffery Ames, MD, Manjula Maganti, MSc, Bethany E Monteith, MD, David C. Hodgson, MD, Vishal Kukreti, MD, John G. Kuruvilla, MD, Anca Prica, MD, Richard Tsang, MD, Alex Sun, MD, Mary Gospodarowicz, MD, Melania Pintilie, MSc, Michael Crump, MD

Blood (2015) 126 (23): 3863.

https://doi.org/10.1182/blood.V126.23.3863.3863

Published: 2015

Journal Articles

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Nancy L. Bartlett, MD, Betsy R. LaPlant, MS, Jing Qi, MD PhD, Stephen M. Ansell, MD PhD, John G. Kuruvilla, MD, Craig B. Reeder, MD, Lim S. Thye, MD, Daniel M. Anderson, MD MPH, Charles Erlichman, MD, Barry A. Siegel, MD

Blood (2014) 124 (21): 800.

https://doi.org/10.1182/blood.V124.21.800.800

Published: 2014

Journal Articles

Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen

Hassan Sibai, Fotios V. Michelis, MDPhD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Jieun Uhm, MD, Vikas Gupta, MD MRCP, MRCPath, John G. Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, PhD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Dennis Dong Hwan Kim, MDPhD

Blood (2014) 124 (21): 3870.

https://doi.org/10.1182/blood.V124.21.3870.3870

Published: 2014

Journal Articles

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

Anna M. Dyszkiewicz-Korpanty, MD PhD, Manjula Maganti, David C. Hodgson, MD, John G. Kuruvilla, MD, Vishal Kukreti, MD, Rodger E. Tiedemann, MD PhD, Alexander Sun, MD, Richard Tsang, MD, Mary Gospodarowicz, MD, Melania Pintilie, Anna Porwit, MDPhD, Michael Crump, MD

Blood (2014) 124 (21): 4447.

https://doi.org/10.1182/blood.V124.21.4447.4447

Published: 2014

NARROW

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial

Failure to Achieve CR with First-Line Treatment Is the Primary Cause of Treatment Failure in T-Cell Lymphoma: The Princess Margaret Cancer Centre Experience

Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Vs. Classical Hodgkin Lymphoma (cHL) at Princess Margaret Cancer Centre

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

Propensity Score Matching Analysis Comparing Reduced Intensity Versus Myeloablative Conditioning in AML/MDS Patients Transplanted with Fludarabine-Busulfan-Low Dose Total Body Irradiation Based Regimen

Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only